Equine case series

Reasons for performing the case series: Intra-articular administration of a 2.5% polyacrylamide hydrogel (2.5% PAAG) has been widely used to treat non-septic arthritis since its introduction to the United Kingdom animal health market, 7 years ago. In order to support an application for Marketing Authorisation (MA), further information, particularly on the safety of the product has been sought from veterinary practices in the United Kingdom.      

Objectives: To retrospectively analyse data from horses treated with 2.5% PAAG from three specialist equine practices in the United Kingdom.

Study design: Retrospective case series.

Methods: Horses showing clinical signs of non-septic arthritis were treated intra-articularly with 0.4ml-4mls (dose dependant on joint/s affected) of 2.5% PAAG, by a treating veterinarian.

The tarsometatarsal (“TMT”) joint, distal intertarsal (“DIT”) joint, fetlock joint and distal interphalangeal (“DIP”) joint accounted for 89.7% of all joints treated. Ancillary treatments commonly included anti-inflammatory and/or hyaluronic acid preparations and less commonly digital neurectomy.         

Results: A total of 341 horses, comprising 804 joints were available for analysis. The veterinary practices involved were all specialist equine centres, whose patients were principally racing thoroughbreds.  70/80 (87.5%) and 232/261 (88.9%) of those treated with 2.5% PAAG and ancillary treatment, and those treated with 2.5% PAAG alone respectively, achieved the anticipated outcome within two months. 15.8% (15/341) received additional injections of 2.5% PAAG, after the initial treatment and 61.6% of horses (210/341) were still in full exercise at least two years after the initial 2.5% PAAG treatment.   Adverse reactions were extremely rare, occurring in only 0.59% of horses (2/341), and both of which responded to conservative therapy.

Limitations: Case selection bias, lack of controls, no blinded assessment. Pending publication. 

Conclusion: This case series shows that 2.5% PAAG is safe and effective at alleviating the clinical signs of non-septic arthritis. There appears to be no major benefit or deleterious effect derived from ancillary treatments. Efficacy results appear consistent with those from previously published studies. 

Arthramid Vet 2.5% PAAG

Precision Medicine

  • Studies show up to 82.5% of horses respond with a successful resolution of joint lameness.
  • Meets Animal Welfare Concerns; Arthramid Vet is not simply a lubricant or painkiller. Its unique biomedical technology that helps heal and restore the joint to healthy function.
  • Made to Last; When compared to traditional treatments for joint lameness, research shows that Arthramid Vet is better and lasts longer with proven efficacy for up to 1- 2 years.
  • One of A Kind; Arthramid Vet's unique and patented IL-X Cross-Linking technology makes it the safest and most effective 2.5% Polyacrylamide (PAAG) Hydrogel available.
  • Addresses Equine Welfare Concerns
  • Long-lasting Clinical Effects of Treatment
  • 82.5% Successful Resolution of Joint Lameness

Get In Touch

Contact Us

First Name:
Last Name:
Your Email:
Phone:
Business Name:
Subject:

IMS Vet
Phone +64 (09) 8013 253
sales@imsvet.com

Arthramid Vet Australia

Registered in Australia to: IMS Vet Pty Limited, 1953 Grampian's Road, Fyans Creek, Victoria 3381. Registered pursuant to the APVMA Number 86728/0320. See www.apvma.gov.au for registration conditions.

Address for Service:
IMSVet, PO Box 1083, Cambridge 3450, New Zealand
Phone +61 (0272) 018 497
sales@imsvet.com